Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Target PharmaSolutions, Inc.
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
2\. Participant has plans for future visits at the site for continued management of IMISC.
You may not be if
1\. Inability to provide written informed consent/assent.
2\. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
Clareo Health | A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
